·Confidence 90%·Breaking
Moderna Stock Jumps 90% on Phase 3 mRNA Cancer Vaccine Success
HOTMRNA ↑ Very strong
Key takeaways
- MRNA: MRNA — Very strong bullish
- Moderna's stock surged over 90% in premarket trading following the successful Phase 3 trial of its mRNA cancer vaccine, signaling a potential breakthrough in
Analysis
Moderna's stock surged over 90% in premarket trading following the successful Phase 3 trial of its mRNA cancer vaccine, signaling a potential breakthrough in
0 likes · 0 dislikes